254 related articles for article (PubMed ID: 25167370)
21. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
Ersmark K; Feierberg I; Bjelic S; Hamelink E; Hackett F; Blackman MJ; Hultén J; Samuelsson B; Aqvist J; Hallberg A
J Med Chem; 2004 Jan; 47(1):110-22. PubMed ID: 14695825
[TBL] [Abstract][Full Text] [Related]
22. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
23. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
24. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
25. Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries.
Beyer BB; Johnson JV; Chung AY; Li T; Madabushi A; Agbandje-McKenna M; McKenna R; Dame JB; Dunn BM
Biochemistry; 2005 Feb; 44(6):1768-79. PubMed ID: 15697202
[TBL] [Abstract][Full Text] [Related]
26. Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria.
Li X; Chen H; Bahamontes-Rosa N; Kun JF; Traore B; Crompton PD; Chishti AH
Biochem Biophys Res Commun; 2009 Mar; 380(3):454-9. PubMed ID: 19174148
[TBL] [Abstract][Full Text] [Related]
27. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
Dali B; Keita M; Megnassan E; Frecer V; Miertus S
Chem Biol Drug Des; 2012 Apr; 79(4):411-30. PubMed ID: 22129033
[TBL] [Abstract][Full Text] [Related]
28. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
29. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
30. Computational analysis of plasmepsin IV bound to an allophenylnorstatine inhibitor.
Gutiérrez-de-Terán H; Nervall M; Dunn BM; Clemente JC; Aqvist J
FEBS Lett; 2006 Oct; 580(25):5910-6. PubMed ID: 17045991
[TBL] [Abstract][Full Text] [Related]
31. Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin.
Hidaka K; Kimura T; Ruben AJ; Uemura T; Kamiya M; Kiso A; Okamoto T; Tsuchiya Y; Hayashi Y; Freire E; Kiso Y
Bioorg Med Chem; 2008 Dec; 16(23):10049-60. PubMed ID: 18952439
[TBL] [Abstract][Full Text] [Related]
32. An aspartyl protease directs malaria effector proteins to the host cell.
Boddey JA; Hodder AN; Günther S; Gilson PR; Patsiouras H; Kapp EA; Pearce JA; de Koning-Ward TF; Simpson RJ; Crabb BS; Cowman AF
Nature; 2010 Feb; 463(7281):627-31. PubMed ID: 20130643
[TBL] [Abstract][Full Text] [Related]
33. A class of potent antimalarials and their specific accumulation in infected erythrocytes.
Wengelnik K; Vidal V; Ancelin ML; Cathiard AM; Morgat JL; Kocken CH; Calas M; Herrera S; Thomas AW; Vial HJ
Science; 2002 Feb; 295(5558):1311-4. PubMed ID: 11847346
[TBL] [Abstract][Full Text] [Related]
34. Structural rationale for the recognition of arginine at P₃ in PEXEL motif containing proteins of Plasmodium falciparum by plasmepsin V.
Guruprasad L; Tanneeru K; Guruprasad K
Protein Pept Lett; 2011 Jun; 18(6):634-41. PubMed ID: 21342099
[TBL] [Abstract][Full Text] [Related]
35. Plasmodium falciparum Plasmepsin V (PfPMV): Insights into recombinant expression, substrate specificity and active site structure.
Boonyalai N; Sittikul P; Yuvaniyama J
Mol Biochem Parasitol; 2015 May; 201(1):5-15. PubMed ID: 25986559
[TBL] [Abstract][Full Text] [Related]
36. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
Ersmark K; Nervall M; Gutiérrez-de-Terán H; Hamelink E; Janka LK; Clemente JC; Dunn BM; Gogoll A; Samuelsson B; Qvist J; Hallberg A
Bioorg Med Chem; 2006 Apr; 14(7):2197-208. PubMed ID: 16307884
[TBL] [Abstract][Full Text] [Related]
37. Identification of first-in-class plasmodium OTU inhibitors with potent anti-malarial activity.
Siyah P; Akgol S; Durdagi S; Kocabas F
Biochem J; 2021 Sep; 478(18):3445-3466. PubMed ID: 34486667
[TBL] [Abstract][Full Text] [Related]
38. Expression and characterisation of plasmepsin I from Plasmodium falciparum.
Moon RP; Tyas L; Certa U; Rupp K; Bur D; Jacquet C; Matile H; Loetscher H; Grueninger-Leitch F; Kay J; Dunn BM; Berry C; Ridley RG
Eur J Biochem; 1997 Mar; 244(2):552-60. PubMed ID: 9119023
[TBL] [Abstract][Full Text] [Related]
39. Plasmodium vivax: collaborative roles for plasmepsin 4 and vivapains in hemoglobin hydrolysis.
Moon SU; Kang JM; Kim TS; Kong Y; Sohn WM; Na BK
Exp Parasitol; 2011 Jun; 128(2):127-32. PubMed ID: 21334328
[TBL] [Abstract][Full Text] [Related]
40. Targeting the Plasmodium falciparum plasmepsin V by ligand-based virtual screening.
Meissner KA; Kronenberger T; Maltarollo VG; Trossini GHG; Wrenger C
Chem Biol Drug Des; 2019 Mar; 93(3):300-312. PubMed ID: 30320974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
